Journal of the Korean Academy of Child and Adolescent Psychiatry : eISSN 2233-9183 / pISSN 1225-729X

Table. 2.

Table. 2.

Studies about the effect of pharmacological treatments on PMU severity

  References Years   Participants   Medication (number)   Dose   Response of PMU   Complications (number or %)
Scott et al [53] 1996 A 13 year old boy Botulinum toxin I.M. in vocal cord 30 U Decreased markedly Hypophonia
Salloway et al [57] 1996 A 28 year old male Botulinum toxin I.M. in vocal cord Initial dose 1.25 U per side 3.75 U every 3 months Not specified Hypophonia
Trimble et al [56] 1998 A 34 year old male Botulinum toxin I.M. in vocal cord 3.75 mouse unit per side Not specified Hypophonia
Kwak et al [54] 2000 30 males & 5 females 23.3±15.5(8-69)year old Botulinum toxin I.M. in cervical(17), upper face(14), lower face(7), vocal cord(4), other(3) 119.9±70.1 U per visit total dose 502.1±779.4 U Decreased markedly Mild neck weakness(4) Transient ptosis(2) Mild dysphagia(2) Hypophonia(1) etc
Jankovic et al [59] 2010 26 males & 3 females 16.5±9.89(7-65)year old Topiramate p.o. Initial dose 25 mg Titration depending on tolerance to 200 mg Mean dose 118 mg YGTSS:14.29±10.47 at baseline →5.00±9.88 at visit 5 PMU CGI improved Headache(3) Diarrhea(3) Abdominal pain(2)Drowsiness(2)etc
Gilbert et al [58] 2014 15 males & 3 females 36.2(18-63)year old Ecopipam p.o. 1-2 wks 50 mg daily 3-8 wks 100 mg daily YGTSS:30.6 at baseline →25.3 at 8 wks there was no significant change in PMU Sedation(39%) Fatigue(33%) Insomnia(33%) Somnolence(28%)etc

CGI: Clinical Global Improvement, PMU: premonitory urge, YGTSS: Yale Global Tic Severity Scale

J Korean Acad Child Adolesc Psychiatry 2019;30:50-6
© 2019 J Korean Acad Child Adolesc Psychiatry